A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
Plaque PsoriasisPsoriatic Arthritis2 moreThe purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment with Remicade® at 5 mg/kg every 8 weeks but decreased thereafter.
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Psoriatic ArthritisThe primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
Psoriatic ArthritisThe purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.
Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
Psoriatic ArthritisThe purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other TNF therapies
Rituxan With or Without Methotrexate in Psoriatic Arthritis
Psoriatic ArthritisThe purpose of this study is to help determine the effectiveness of rituxan (with or without methotrexate) in the treatment of psoriatic arthritis.
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
Psoriatic ArthritisThis study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.
Enbrel® in Psoriatic Arthritis
PsoriasisThis study is testing the effect of etanercept in treating both the skin and joint symptoms of psoriatic arthritis patients. Enbrel®, also known as etanercept, has already been approved by the Federal Food Drug Administration for the treatment of psoriatic arthritis. It is taken as an injection under the skin. Participants in the trial will be offered etanercept free of charge to be self-injected once weekly for 24 weeks. During that period they will have 5 appointments at the study center and will also be asked to complete assessments of their health.
A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
ArthritisPsoriaticThe purpose of this study is to evaluate the safety and efficacy (improvement of signs and symptoms) of subcutaneous (under the skin) injections of golimumab for the treatment of active psoriatic arthritis (PsA). Efficacy will be measured by reduction in the signs and symptoms of active PsA, including effects on joint pain and swelling, changes on x-ray related to joint damage, psoriasis skin lesions, physical function, and quality of life.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response...
ArthritisPsoriaticThe purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the reduction in signs and symptoms of joint disease.
CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis.
Psoriatic ArthritisHand OsteoarthritisA randomized, placebo-controlled trial with blinded outcome assessments will be conducted to evaluate the efficacy and safety of CBD in patients with Hand-OA and PsA during a 12-week treatment period.